ISSN: 2640-8007
Open Journal of Bacteriology
Mini Review       Open Access      Peer-Reviewed

Microbiota Disease

Álvaro Zamudio-Tiburcio1*, Héctor Bermúdez-Ruiz2 and Pedro Antonio Reyes-López3

1Department of Gastroenterology, Intestinal Microbiota Transplant Unit, Hospital Trinidad. Mexico City, Mexico
2Endoscopy Service, Oncology Hospital, National Medical Center, XXI century, Mexican Social Security Institute, Transplant of Intestinal Microbiota, Hospital Trinidad, Mexico City, Mexico
3Research Department, National Institute of Cardiology “Ignacio Chávez”, Intestinal Microbiota Transplant, Hospital Trinidad, Mexico, City, Mexico
*Corresponding author: Álvaro Zamudio-Tiburcio, Department of Gastroenterology, Intestinal Microbiota Transplant Unit, Hospital Trinidad, Mexico City, Tlaxcala 84, First floor, Suite 13, Roma sur, Town hall, Cuauhtémoc, ZIP: 06770, Mexico City, Mexico, Tel: +52 (55) 2155-3877; + 52 (55) 1085-2760; Ext-138; Mobile: (55) 1005-7690; E-mail: alzati58@hotmail.com
Received:22 July, 2019 | Accepted: 12 August, 2019 | Published: 13 August, 2019

Cite this as

Tiburcio ÁZ, Ruiz HB, Reyes-López PA (2019) Microbiota Disease. Open J Bac 3(1): 008-010. DOI: 10.17352/ojb.000010

The authors try to describe the Microbiota Diseases, like a process thatbrings together a number of conditions, caused by dysbiosis and that occur fudamentally in the devices and systems: Immunological, Gastrointestinal, Dermatological, Psychiatric, Neurological, Endocrinological and others. In order to draw attention to the need to strengthen ties of union between all those interested in the subject, to shorten resources, times and establish development criteria, this review is published. Without a doubt, it will make this Diseases, accepted, can be strengthened and direct talents for the benefit of the millions of human beings affected by this problem.

What are Microbiota Diseases?

Some authors have determined it as dysbiosis (dysbacteriosis). Microbiota imbalance that can be produced to various causes [1-3]. We consider this process, which is actually caused by an instability of the Microbiota, produces a series of diseases, that can occur generally in the following systems [4].

• Immune

• Gastrointestinal

• Dermatological

• Psychiatric

• Neurological

• Endocrinological, and others.

With regard to the immune system, some authors have referred to allergie diseases in chilhood [5-7]. Others link lactose intolerance as a cause by Microbiota disorders [8-10]. Food intolerance due to dysbiosis is also reported by numerous authors [11-13]. Asthma is a condition frequently considered due to alterations suffered by the microbiota [14-16]. In relation to the gastrointestinal disorders, generated by pathology of the microbiota, pseudo-membranous enterocolitis is found [17-21], multi-scanned bastion and in which the results have been more favorable and surprising and, which is the basis for the exploration of countless gastrointestinal conditions and organs of the system, such as the liver [22-24].

Moreover, what is truly transcendent is the effect that Microbiota has on cancerous processes. It has been indicated in the period of remission, in order to influence the immunological improvement, although other authors go little further. Now, it is known that the intestinal microbiota generates extraordinary symbiotic relationship with its host. This relationship, produces significant changes in immunity, metabolism and nutrition, is altered in cancer, through inflammatory processes, which translate significant alterations. It has been observed that Intestinal Microbiota Transplant helps immunological therapy, which is provided to this type of patients, by reconstructing the microbiome and improving the metabolism of bile acids [25-27].

The positive incidence of the microbiota diseases in conditions, has been observed such as Functional Digestive Disorders [28,29].

In relation to various dermatological pathology, IMT (Intestinal Microbiota Transplantation) has also been attempted and, although it substantially improves the aggregate, digestive and psychiatric processes, as regards the dermatological process, the impact is less [30]. Is this type of pathology what requires more than IMT is a dermal microbiota transplant? Other articles state the opposite, and affirm that the transplant is highly effective in atopic dermatitis, not only in humans, but also in dogs [31].

All of the above makes us raise the following questions: For dermatological disorders, not only do you have to use intestinal microbiota, but also the one that inhabits the skin?

For alterations of the genital microbiota, in addition to the intestinal microbiota, is it necessary to use vaginal microbiota? And... So on, in all the affected microbiota that exist.

Psychiatric aspects, such as Anxiety, Anorexia Nervosa and others, have been studied, with variable results, although in most cases, especially in Anxiety, the results are favorable [32-35].

The alterations in Pediatrics due to the Microbiota Diseases are diverse and numerous and encouraging results have been obtained [36-40].

In relation to neurological processes, in which the microbiota and its transplant act beneficially, we find that the following conditions have been reported as favored [41-46].

Alzheimer

Autism

Multiple Sclerosis

Parkinson

Neurodegenerative Disorders

Neurodevelopment Disorders

What about the endocrinological system? There are few diseases in which significant role of dysbiosis has been adduced. Thus we see that Hashimoto’s Disease, Type 1 Diabetes mellitus, Metabolic Syndrome and Obesity and Type 2 Diabetes Mellitus, alterations of the Microbiota are observed, which can be improved with the Transplant of the same [47-50].

Conclusion

However, with the increasing number of articles, where dysbiosis is defined as an forger of inflammatory processes, and the frequent occurrence of multiple diseases, triggered by a single disease, which is the alteration of the microbiota, which we define as Microbiota Diseases, it is worth considering the current proposal, in order to systematize the management of these conditions.

Likewise, the use of Intestinal Microbiota Transplantation, in a multitude of conditions, including various types of cancer, with encouraging results, deserves to receive in-depth analysis, in order to evaluate carrying it out, in patients, victims of these frequent processes.

Finally, given the small number of Microbiota Banks in the world, we hope that this article serves as a stimulus, to develop a greater number of them and, strengthen the use of IMT and research, of the different microorganisms that constitute it.

Informed consent

The authors obtained informed written consent from the patients, in order to develop this article.

  1. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ (2015) Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 26: 26191. Link: http://bit.ly/2TpQmIk
  2. Kump PK, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, et al. (2013) Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19: 2155-2165. Link: http://bit.ly/2MVCJ2p
  3. Walker AW, Lawley TD (2013) Therapeutic modulation of intestinal dysbiosis. Pharmacol Res 69: 75-86. Link: http://bit.ly/31xok0r
  4. Tiburcio ÁZ, Ruiz HB, Antonio P, López R (2019) Microbiota Disease Treated With Intestinal Microbiota Transplant. Annals of Microbiology and Immunology 2: 1015.
  5. Russell SL, Finlay BB (2012) The impact of gut microbes in allergic diseases. Curr Opin Gastroenterol 28: 563-569. Link: http://bit.ly/2YP0jFm
  6. Noverr MC, Huffnagle GB (2005) The “Microflora Hypothesis” of allergic diseases. Clin Exp Allergy 35: 1511-1520. Link: http://bit.ly/31Cb8HI
  7. Logan AC, Jacka FN, Craig JM, Prescott SL (2016) The Microbiome and Mental Health: Looking Back, Moving Forward with Lessons from Allergic Diseases. Clin Psychopharmacol Neurosci 14: 131-47. Link: http://bit.ly/2yXeI2Q
  8. Prescott SL, Pawankar R, Allen KJ, Campbell DE, Sinn J, et al. (2013) A global survey of changing patterns of food allergy burden in children. World Allergy Organ J 6: 21. Link: http://bit.ly/2yY2h6R
  9. Pascal M, Pérez-Gordo M, Caballero T, Escribese MM, López Logo MN, et al. (2018) Microbiome and Allergic Diseases. Front Immunol 9: 1584. Link: http://bit.ly/2MfsczI
  10. Marsland BJ, Salami O (2015) Microbiome influences on allergy in mice and humans. Curr Opin Immunol 36: 94-100. Link: http://bit.ly/2MdIicZ
  11. Zhao W, Ho HE, Bunyavanich S (2019) The gut microbiome in food allergy. Ann Allergy Asthma Immunol 122: 276-282. Link: http://bit.ly/2N5hsmK
  12. Blázquez AB, Berin MC (2017) Microbiome and Food Allergy. Transl Res 179: 199-203. Link: http://bit.ly/2TtpmaW
  13. Plunkett CH, Nagler CR (2017) The influence of the microbiome on allergic sensitization to food. J Immmunol 198: 581-589. Link: http://bit.ly/2KtqDvM
  14.  Lu J, Xiong L, Zhang X, Liu Z, Wang S, et al. (2017) The role of Lower Airway Dysbiosis in Asthma: Dysbiosis and Asthma. Mediators Inflamm 2017: 3890601. Link: http://bit.ly/2TpU04Y
  15. Sokolowska M, Frei R, Lunjani N, Akdis CA, O´Mahony L (2018) Microbioma and asthma. Asthma Res Pract 4: 1. Link: http://bit.ly/2Z51FXr
  16. Begley L, Madapoosi S, Opron K, Ndum O, Baptist A, et al. (2018) Gut microbiota relationships to lung function and adult asthma phenotype: a pilot study. BMJ Open Resp Dis 5: e000324. Link: http://bit.ly/2OPTQoJ
  17. Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, et al. (2014) Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58: 1515-1522. Link: http://bit.ly/2YXJx1L
  18. Yoon SS, Brandt LJ (2010) Treatment of refractory/recurrent C. difficile associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 44: 562-566. Link: http://bit.ly/2KwoUWH
  19. Rubin TA, Gessert CE, Aas J, Bakken JS (2013) Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 19: 22-26.Link: http://bit.ly/33nBvme
  20. Rossen NG, McDonald JK, de Vries EM, D´Haens GR, de Vos WM, et al. (2015) Fecal microbiota transplantation as a Nove therapy in gastroenterology: systematic review. World J Gastroenterol 21: 5359-5371. Link: http://bit.ly/2OPVsyN
  21. Neelakanta A, Moudgal V, Upadhyay N, Valenstein P, Gunaratnam NT (2012) Successful Treatment of Refractory Clostridium difficile Infection (Cdi) With Intestinal Microbiota Transplant (IMT) in Two Patients With Inflammatory Bowel Disease (IBD) and Its Effects on IBD. Gastroenterology 142: S-395. Link: http://bit.ly/2YTnc9R
  22. Benninga MA, Nurko S, Faure C, Hyman PE, Roberts IS, et al. (2016) Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology pii: S0016-5085. Link: http://bit.ly/33wPVAL
  23. Porras D, Nistal E, Martínez-Flores S, Olcoz JL, Jover R, et al. (2019) Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in German–Free Mice. Mol Nutr Food Res 63: e1800930. Link: http://bit.ly/2YLg53G
  24. Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, et al. (2018) Fecal microbiota transplantation: a promising strategy in preventing the progession of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther 18: 1061-107. Link: http://bit.ly/33u1DMq
  25. Chen D, Wu J, Jin D, Wang B, Cao H (2018) Fecal microbiota Transplantation in cancer management: Current status and perspectives. Int J Cancer. Link: http://bit.ly/2KHIOge
  26. Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, et al. (2017) The microbiome and hepatobiliary‐pancreatic cancers. Cancer letters 402: 9-15. Link: http://bit.ly/2Z8LRY8
  27. Arthur JC, Perez‐Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, et al. (2012) Intestinal inflammation targets cancer‐ inducing activity of the microbiota. Science 338: 120-123. Link: http://bit.ly/2yStec9
  28. Pinn DM, Aroniadis OC, Brandt LJ (2015) Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional Gastrointestinal disorders (FGID)?. Neurogastroenterol Motil 27: 19-29. Link: http://bit.ly/2TyqQRm
  29. Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, et al. (2015) Fecal Microbiota Transplantation Broadening Its Application beyond Intestinal Disorders. World J Gastroenterol 21: 102-111. Link: http://bit.ly/33unzH3
  30. Álvaro Zamudio-Tiburcio, Héctor Bermúdez-Ruiz, Pedro Antonio Reyes-López (2019) Psoriasis is Candidate for Intestinal Microbiota Transplantation? EC Microbiology. Link: http://bit.ly/2MVIm0x
  31. Craig JM (2016) Atopic dermatitis and the intestinal microbita in humans and dogs. Vet Med Sci 2: 95-105. Link: http://bit.ly/2KLBf7Z
  32. Sommer F, Bäckhed F (2013) The gut microbiota-masters of host Development and physiology. Nat Rev Microbiol 11: 227-38. Link: http://bit.ly/2YXMAqJ
  33. Sommer F, Bäckhed F (2013) The gut microbiota-masters of host Development and physiology. Nat Rev Microbiol 11: 227-38. Link: http://bit.ly/2YXMAqJ
  34. Kitazawa M, Kurokawa S, Kishimoto T, Mizuno S, Masaoka T, et al. (2018) The effect of fecal microbiota transplantation on psychiatric symptoms among paoents with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. J Affect Disord 235: 506-512. Link: http://bit.ly/2yWMF3m
  35. Li N, Wang Q, Wang Y, Sun A, Lin Y, et al. (2019) Fecal microbiota transplantation from chronic inpredictable mild stress mice donors affects anxiety-like and depression-like behavior in recipient mice via the gut microbiota-inflammation-brain axis. Stress 22: 592-602. Link: http://bit.ly/31xwFRG
  36. Gurram B, Sue PK (2019) Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr. Link: http://bit.ly/2ZYF93Z .
  37. Cho S, Spencer E, Hirten R, Grinspan A, Dubinsky MC (2019) Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 68: 343-347. Link: http://bit.ly/2Z1ZMe4
  38. Wang AY, Popov J, Pai N (2016) Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease. World J Gastroenterol 22: 10304-10315. Link: http://bit.ly/2KtScVG
  39. Kump P, Högenauer C (2016) Any Future for Fecal Microbiota transplantation as Treatment Strategy for Inflammatory Bowel Diseases. Dig Dis 74-81. Link: http://bit.ly/2H3zBO5
  40. Hourigan SK, Oliva-Hemker M (2016) Fecal microbiota transplantation in children: a brief review. Pediatr Res 80: 2-6. Link: http://bit.ly/33xIuJh
  41. Jiang C, Li G, Huang P, Liu Z, Zhao B (2017) The Gut Microbiota and Alzheimer´s Disease. J Alzheimers Dis 58: 1-15. Link: http://bit.ly/2TseCJJ
  42. Dae-Wook-K, Adams JB, Coleman DM, Pollard EL, Maldonado J, et al. (2019) Long-term benefit of Microbiota Transfer Therapy on autism symptonms and gut microbiota. Scientific Report 9: 5821. Link: https://go.nature.com/31yWLUr
  43. Wing AC, Kremenchutzky M (2019) Multiple sclerosis and faecal microbiome transplantation: are you going to eat that? Benef Microbes 10: 27-32. Link: http://bit.ly/2YZ4IED
  44. Flameling IA, Rijkers GT (2018) Gut Microbiota Brain axis. Fecal Microbiota Transplants as a Treatment Option for Parkinson´s Disease. Edited by Alper Evrensel, Üsküdar Unversity.
  45. Sasmita AO ( 2019) Modification of the gut microbiome to combat neurodegeneration. Rev Neurosci. Link: http://bit.ly/31te4Gu
  46. Staley C, Khoruts A, Sadowky MJ (2017) Contemporary Applicatons of Fecal Microbiota Transplantation to Treat Intestinal Diseases in humans. Arch Med Res 48: 766-773. Link: http://bit.ly/2YEZpLg
  47. Zhao F, Feng L, Li J, Zhao L, Liu Y,et al. (2018) Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients. Thyroid 28: 175-186. Link: http://bit.ly/2KKiF06
  48.  Xu MQ, Cao HL, Qiang WQ, Wang S, Cao XC, et al. (2015) Fecal microbiota transplantation broadening its application beyond Intestinal disorderds. World J Gatroenterol 21: 102-111. Link: http://bit.ly/33unzH3
  49.  De Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M (2017) Fecal Microbiota transplatation in metabolic syndrome: History, present and future. Gut Microbes 8: 253-267. Link: http://bit.ly/2MY7ELq
  50. Harsch IA, Konturek PC (2018) The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases. Med Sci 6: pii: E32. Link: http://bit.ly/2OUaHHg
© 2019 Tiburcio ÁZ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.